The higher immune infiltration is characterized by elevated tumor-infiltrating lymphocytes (TILs) (16), increased levels of PD-L1 expression in tumor cells and immune cells (17, 18), and a greater number of non-synonymous mutations, which produce tumor-specific neoantigens, activate neoantigen-specific T cells, and trigger anti-tumor immune responses (19, 20). The gene discussed is CD274; the disease is neoplasm.